As a subtype of invasive breast cancer (IBC), luminal breast cancer is characterized by the expression of hormone receptors, particularly estrogen receptor (ER) and progesterone receptor (PR), and is typically HER2-negative. This evidence concerns the gene NR4A1 and inflammatory breast carcinoma.